fatty amide - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	fatty amide	go back to main search page
Accession:	CHEBI:29348	browse the term
Definition:	A monocarboxylic acid amide derived from a fatty acid.
Synonyms:	related_synonym:	Aliphatic amide; Formula=CHNOR2; fatty amides
	alt_id:	CHEBI:13247; CHEBI:22310; CHEBI:22330; CHEBI:2572; CHEBI:35749; CHEBI:38838
	xref:	KEGG:C02244; LIPID_MAPS_class:LMFA08
	cyclic_relationship:	is_conjugate_acid_of CHEBI:229684

show annotations for term's descendants Sort by:
Rat (829) Mouse (822) Human (847) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (3) Green Monkey (0) Naked Mole-rat (0) All
Genes (829)

alpha-Sanshool

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenomedullin

increases secretion

sanshool analog results in increased secretion of ADM protein

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

potassium two pore domain channel subfamily K member 18

affects response to substance
multiple interactions
decreases activity

KCNK18 protein affects the susceptibility to sanshool
sanshool inhibits the reaction [KCNK18 protein results in increased transport of Potassium]
sanshool results in decreased activity of KCNK18 protein

NCBI chr 1:258,374,671...258,388,945
Ensembl chr 1:258,374,671...258,388,945

G

potassium two pore domain channel subfamily K member 3

multiple interactions
decreases activity
affects response to substance

sanshool inhibits the reaction [[KCNK3 protein binds to KCNK9 protein] which results in increased transport of Potassium]; sanshool inhibits the reaction [KCNK3 protein results in increased transport of Potassium]; sanshool results in decreased activity of [KCNK3 protein binds to KCNK9 protein]
sanshool results in decreased activity of KCNK3 protein
KCNK3 protein affects the susceptibility to sanshool

NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153

G

potassium two pore domain channel subfamily K member 9

affects response to substance
decreases activity
multiple interactions

KCNK9 protein affects the susceptibility to sanshool
sanshool results in decreased activity of KCNK9 protein
sanshool inhibits the reaction [[KCNK3 protein binds to KCNK9 protein] which results in increased transport of Potassium]; sanshool inhibits the reaction [KCNK9 protein results in increased transport of Potassium]; sanshool results in decreased activity of [KCNK3 protein binds to KCNK9 protein]

NCBI chr 7:104,429,186...104,473,924
Ensembl chr 7:104,437,934...104,473,175

anandamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases export

ABCB1 protein results in increased export of anandamide

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]
anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein

PMID:30610963 PMID:34756920

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acyl-CoA oxidase 1

multiple interactions

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA]

NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371

G

amyloid beta precursor protein

decreases response to substance
decreases metabolic processing
decreases abundance

anandamide results in decreased susceptibility to APP protein
APP protein results in decreased metabolism of anandamide
APP protein results in decreased abundance of anandamide

PMID:22233683 PMID:26976670

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arrestin, beta 2

multiple interactions

anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

bradykinin receptor B1

multiple interactions
decreases activity

AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

caspase 3

increases cleavage
multiple interactions

anandamide results in increased cleavage of CASP3 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CD36 molecule

increases expression

anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

glycoprotein hormones, alpha polypeptide

decreases expression

anandamide results in decreased expression of CGA mRNA

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

cannabinoid receptor 1

affects activity
increases response to substance
decreases expression
affects binding
increases activity
multiple interactions

anandamide affects the activity of CNR1 protein
CNR1 protein results in increased susceptibility to anandamide
anandamide results in decreased expression of CNR1 protein
anandamide binds to CNR1 protein
anandamide results in increased activity of CNR1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1]
[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]

PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 More...

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

affects activity
affects binding
multiple interactions

anandamide affects the activity of CNR2 protein
anandamide binds to CNR2 protein
anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]

PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

cAMP responsive element binding protein 1

multiple interactions
decreases phosphorylation

anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]
anandamide results in decreased phosphorylation of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

decreases abundance

CRH protein results in decreased abundance of anandamide

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions
increases metabolic processing

cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein
4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]

PMID:21949157 PMID:26513129 PMID:29441458

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

anandamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

endogenous retrovirus group FRD member 1, envelope

decreases expression

anandamide results in decreased expression of ERVFRD-1 mRNA

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

coagulation factor III, tissue factor

multiple interactions
increases expression

anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
anandamide results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid amide hydrolase

increases degradation
increases response to substance
decreases metabolic processing
multiple interactions
affects expression

FAAH results in increased degradation of anandamide
FAAH gene mutant form results in increased susceptibility to anandamide
FAAH gene mutant form results in decreased metabolism of anandamide
FAAH protein results in increased degradation of anandamide
[Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide]
anandamide affects the expression of FAAH protein
[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]

PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 More...

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 1

multiple interactions
affects abundance
affects binding

11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein]
FABP1 protein affects the abundance of anandamide
FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]

PMID:29414765 PMID:30232874

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein]
anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein

PMID:9748483 PMID:15601931 PMID:19515121

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

interferon gamma

multiple interactions

anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

increases expression

anandamide results in increased expression of IGF1 protein

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 12B

multiple interactions

[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 beta

multiple interactions

anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]

PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin

decreases abundance
multiple interactions
decreases activity
decreases transport

LEP protein results in decreased abundance of anandamide
Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide]
LEP protein results in decreased activity of anandamide
LEP protein results in decreased transport of anandamide

PMID:16154199 PMID:29967158

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

increases expression

anandamide results in increased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 3

increases expression

anandamide results in increased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions
increases expression

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nitric oxide synthase 2

multiple interactions

anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

PMID:11891798 PMID:15748152

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

increases cleavage

anandamide results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

peroxisome proliferator activated receptor alpha

multiple interactions

anandamide binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
increases metabolic processing

[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide
anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein
PTGS2 results in increased metabolism of anandamide
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]

PMID:16330497 PMID:17245358 PMID:20702753

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin P

multiple interactions
increases expression

anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein]
anandamide results in increased expression of SELP protein

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

anandamide results in increased expression of TIMP1 mRNA
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
increases abundance

anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]
TNF protein results in increased abundance of anandamide
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]

PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions
increases response to substance
increases activity
affects response to substance
affects binding

3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]
TRPV1 protein results in increased susceptibility to anandamide
anandamide results in increased activity of TRPV1 protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein]
anandamide binds to TRPV1 protein

PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 More...

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

vascular endothelial growth factor A

multiple interactions

anandamide results in decreased expression of and results in decreased secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

arachidonyl-2'-chloroethylamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

agouti related neuropeptide

decreases expression

arachidonyl-2-chloroethylamide results in decreased expression of AGRP mRNA

NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584

G

AKT serine/threonine kinase 1

decreases phosphorylation

arachidonyl-2-chloroethylamide results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

angiopoietin 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT1 protein]

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT2 protein]

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

arginine vasopressin

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2, apoptosis regulator

multiple interactions
increases expression

[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein
arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

CART prepropeptide

decreases expression
multiple interactions

arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA
[arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 3

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 4

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

CD86 molecule

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cannabinoid receptor 1

multiple interactions

CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]

PMID:12734338 PMID:27455076 PMID:29033935

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

diacylglycerol lipase, alpha

multiple interactions
increases expression

ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein

NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232

G

diacylglycerol lipase, beta

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]

NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154

G

DNA-damage inducible transcript 3

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dopamine receptor D2

decreases expression

arachidonyl-2-chloroethylamide results in decreased expression of DRD2 mRNA

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

estrogen-related receptor gamma

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]

PMID:27455076 PMID:30019168 PMID:31912162

NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397

G

fibrinogen alpha chain

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA]

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibrinogen beta chain

multiple interactions
increases expression

GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA]

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

fibroblast growth factor 21

increases expression
increases secretion
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA
arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

fibrinogen gamma chain

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA]

NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322

G

forkhead box O1

multiple interactions
decreases phosphorylation

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]
arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glutathione-disulfide reductase

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hypocretin neuropeptide precursor

increases expression

arachidonyl-2-chloroethylamide results in increased expression of HCRT mRNA

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

interleukin 6

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

PMID:26671069 PMID:26847930 PMID:30761839

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

myeloperoxidase

multiple interactions
increases activity

Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 2

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear respiratory factor 1

multiple interactions
decreases expression

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

oligodendrocyte transcription factor 2

increases expression

arachidonyl-2-chloroethylamide results in increased expression of OLIG2 protein

NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152

G

oxytocin/neurophysin I prepropeptide

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

poly (ADP-ribose) polymerase 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

pro-melanin-concentrating hormone

multiple interactions
increases expression

arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]
arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA

NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250

G

proopiomelanocortin

multiple interactions
decreases expression

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]
arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member A

multiple interactions
increases activity

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

transcription factor A, mitochondrial

decreases expression
multiple interactions

arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

tumor necrosis factor

increases expression
multiple interactions

arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased phosphorylation of TRP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vascular endothelial growth factor A

multiple interactions

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

multiple interactions

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

bucladesine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]

PMID:20083572 PMID:23227865 PMID:23362264

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions

Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions
increases activity
affects localization
increases expression

Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]
Bucladesine results in increased activity of ABCC2 protein
Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein]

PMID:12029626 PMID:26049102 PMID:29052767

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

acetylcholinesterase

increases activity
increases expression

Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form
Bucladesine results in increased expression of ACHE mRNA

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

adrenomedullin

decreases expression

Bucladesine results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

angiotensinogen

multiple interactions

AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

affects localization
increases activity
multiple interactions

Bucladesine affects the localization of AHR protein
Bucladesine results in increased activity of AHR protein
Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aryl-hydrocarbon receptor repressor

multiple interactions

Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA]

NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673

G

adenylate kinase 5

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA

NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458

G

5'-aminolevulinate synthase 1

multiple interactions

[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

ANTXR cell adhesion molecule 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA

NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232

G

annexin A2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

apolipoprotein A1

multiple interactions

27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]

PMID:20083572 PMID:23227865

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

androgen receptor

multiple interactions

[Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

Rho/Rac guanine nucleotide exchange factor 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA

NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355

G

activating transcription factor 1

multiple interactions

Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]]

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

activating transcription factor 2

multiple interactions
increases phosphorylation
increases expression

Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form]
Bucladesine results in increased phosphorylation of ATF2 protein

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

ATPase phospholipid transporting 11A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA

NCBI chr16:76,657,752...76,767,640
Ensembl chr16:76,657,752...76,767,640

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

ATPase H+ transporting V0 subunit C

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA

NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500

G

BCL2 associated X, apoptosis regulator

multiple interactions

adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

branched chain amino acid transaminase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA

NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597

G

branched chain ketoacid dehydrogenase kinase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA

NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Bucladesine results in decreased expression of BCL2 protein

PMID:10697531 PMID:16822680

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 13

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA

NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985

G

brain-derived neurotrophic factor

multiple interactions
increases expression

1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA

PMID:19189864 PMID:29698629

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

Bet1 golgi vesicular membrane trafficking protein-like

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA

NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040

G

BICD cargo adaptor 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA

NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434

G

bone morphogenetic protein 4

multiple interactions

Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA]

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

barttin CLCNK type accessory subunit beta

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA

NCBI chr 5:121,251,774...121,260,571
Ensembl chr 5:121,251,774...121,260,571

G

complement C1r

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA

NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484

G

calmodulin 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

calreticulin

increases stability

Bucladesine results in increased stability of CALR protein

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calpain 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

caspase 3

multiple interactions

Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

calpastatin

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

caveolin 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA

NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244

G

C-C motif chemokine ligand 3

multiple interactions

Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cellular communication network factor 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin B1

multiple interactions

[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

increases expression
multiple interactions

Bucladesine results in increased expression of CCND1 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein

PMID:16718685 PMID:21693435 PMID:22534328

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

increases expression

Bucladesine results in increased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

Cd69 molecule

decreases expression

Bucladesine results in decreased expression of CD69 protein

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

Cd80 molecule

multiple interactions

Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CDC42 binding protein kinase alpha

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA

NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Bucladesine results in increased expression of CDKN1A protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]

PMID:16718685 PMID:20823114 PMID:22534328

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Bucladesine results in increased expression of CDKN1B protein

PMID:16718685 PMID:21693435

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein beta

increases expression
multiple interactions

Bucladesine results in increased expression of CEBPB protein
Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein]

PMID:19282384 PMID:19698295

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein zeta

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA

NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600

G

choline O-acetyltransferase

multiple interactions
increases expression

[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein
Bucladesine results in increased expression of CHAT protein
Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein]

PMID:16724269 PMID:20361958 PMID:29665406

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

claudin 5

increases expression

Bucladesine results in increased expression of CLDN5 mRNA

NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992

G

cyclic nucleotide gated channel subunit beta 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA

NCBI chr19:9,726,595...9,791,111
Ensembl chr19:9,726,595...9,791,173

G

collagen type I alpha 1 chain

multiple interactions

Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

PMID:11576339 PMID:16430859

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

multiple interactions

Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type VI alpha 2 chain

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

collagen type VI alpha 3 chain

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

cytochrome c oxidase subunit 6A2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA

NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274

G

complexin 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA

NCBI chr14:1,184,677...1,216,392

G

cAMP responsive element binding protein 1

increases phosphorylation
multiple interactions

Bucladesine results in increased phosphorylation of CREB1 protein
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein]

PMID:12164941 PMID:18787026 PMID:19282384 PMID:36565944

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

multiple interactions

[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]

PMID:19282384 PMID:20685861 PMID:36565944

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cAMP responsive element modulator

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

crystallin, alpha B

multiple interactions

Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein]

NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157

G

colony stimulating factor 1 receptor

multiple interactions

Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA]

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

C-terminal binding protein 1

multiple interactions
affects localization

Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]
Bucladesine affects the localization of CTBP1 protein

NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821

G

C-terminal binding protein 2

affects localization
multiple interactions

Bucladesine affects the localization of CTBP2 protein
Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]

NCBI chr 1:187,782,064...187,918,115
Ensembl chr 1:187,782,682...187,920,222

G

catenin beta 1

increases phosphorylation

Bucladesine results in increased phosphorylation of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

CTP synthase 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA

NCBI chr X:31,645,873...31,786,733
Ensembl chr X:31,645,873...31,786,733

G

C-X-C motif chemokine ligand 12

decreases expression

Bucladesine results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome b5 domain containing 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA

NCBI chr10:54,113,428...54,117,744
Ensembl chr10:54,113,438...54,117,911

G

cytochrome P450, family 11, subfamily a, polypeptide 1

increases expression
multiple interactions

Bucladesine results in increased expression of CYP11A1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]
[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA]

PMID:21693180 PMID:21979172 PMID:23200735 PMID:35987080

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases expression
multiple interactions

Bucladesine results in increased expression of CYP11B1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11B1 mRNA]

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 11, subfamily b, polypeptide 3

multiple interactions
increases expression

fluorene-9-bisphenol affects the reaction [Bucladesine results in increased expression of CYP11B2 mRNA]

NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression
increases expression
multiple interactions

Bucladesine results in decreased expression of CYP17A1 mRNA
Bucladesine results in increased expression of CYP17A1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP17A1 mRNA]
[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA]

PMID:21458522 PMID:21693180 PMID:23200735 PMID:35987080

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases expression
multiple interactions

Bucladesine results in increased expression of CYP19A1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP19A1 mRNA]

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]

PMID:1849469 PMID:16901605

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

Bucladesine results in increased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

decorin

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein]

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

DEAD-box helicase 27

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA

NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372

G

desmin

multiple interactions

[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA

PMID:19089455 PMID:20823114

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

DExH-box helicase 9

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA

NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069

G

iodothyronine deiodinase 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

deoxythymidylate kinase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA

NCBI chr 9:94,315,552...94,324,386
Ensembl chr 9:94,315,552...94,324,870

G

ectodysplasin-A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA

NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

EGF containing fibulin extracellular matrix protein 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA

NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018

G

epidermal growth factor

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

early growth response 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

enolase 2

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

erythrocyte membrane protein band 4.1 like 4A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA

NCBI chr18:25,405,461...25,615,392
Ensembl chr18:25,406,057...25,615,149

G

Eph receptor A3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA

NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900

G

estrogen receptor 1

increases expression
multiple interactions

Bucladesine results in increased expression of ESR1 mRNA
[Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA]

PMID:21693180 PMID:23200735

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

EYA transcriptional coactivator and phosphatase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA

NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

multiple interactions

[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]]

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

G

fatty acid desaturase 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

increases expression
multiple interactions

Bucladesine results in increased expression of FAS mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

F-box protein 11

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA

NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662

G

F-box and WD repeat domain containing 5

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA

NCBI chr 3:8,322,543...8,327,092
Ensembl chr 3:8,322,543...8,327,092

G

Fc epsilon receptor II

decreases expression

Bucladesine results in decreased expression of FCER2 protein

NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476

G

FYVE, RhoGEF and PH domain containing 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA

NCBI chr X:20,023,746...20,066,734
Ensembl chr X:20,023,746...20,066,566

G

fibroblast growth factor 2

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 9

multiple interactions

FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

filamin A interacting protein 1-like

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA

NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415

G

FKBP prolyl isomerase 5

multiple interactions

[bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA]

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

fibronectin 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

affects expression
multiple interactions
increases expression

Bucladesine affects the expression of FOS protein
Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein]
Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein

PMID:7798212 PMID:9187264 PMID:19282384

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box O1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]

PMID:20823114 PMID:36682589

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

fascin actin-bundling protein 2, retinal

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA

NCBI chr10:105,634,783...105,641,322
Ensembl chr10:105,634,783...105,641,322

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
increases expression

IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]]
Bucladesine results in increased expression of G6PC1 mRNA; Bucladesine results in increased expression of G6PC1 protein

PMID:22859313 PMID:26064446

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glycyl-tRNA synthetase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA

NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609

G

1,4-alpha-glucan branching enzyme 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA

NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210

G

guanylate binding protein 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

glucosaminyl (N-acetyl) transferase 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA

NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611

G

growth differentiation factor 3

affects expression
multiple interactions

Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein
bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein]

NCBI chr 4:155,831,572...155,835,953
Ensembl chr 4:155,830,909...155,835,937

G

glial cell derived neurotrophic factor

multiple interactions

[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]]

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

GIPC PDZ domain containing family, member 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA

NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997

G

gap junction protein, alpha 1

multiple interactions
increases expression

GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein]

PMID:11741589 PMID:16718685

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glycerol-3-phosphate dehydrogenase 1

multiple interactions

Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA]

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

G patch domain and KOW motifs

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA

NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384

G

glycoprotein nmb

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

glutathione S-transferase alpha 1

multiple interactions
increases expression

KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

increases expression
multiple interactions

Bucladesine results in increased expression of GSTA2 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA]

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 4

increases expression
multiple interactions

Bucladesine results in increased expression of GSTA4 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA]

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

hypoxia inducible factor 1 subunit alpha

increases expression

Bucladesine results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
increases expression

[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]

PMID:35987080 PMID:38603619

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

homeobox A1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA]

NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504

G

hydroxysteroid (17-beta) dehydrogenase 1

decreases expression
multiple interactions

Bucladesine results in decreased expression of HSD17B1 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in decreased expression of HSD17B1 mRNA]

NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927

G

hydroxysteroid (17-beta) dehydrogenase 12

increases expression

Bucladesine results in increased expression of HSD17B12 mRNA

NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

increases expression

Bucladesine results in increased expression of HSD3B1 mRNA

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

increases expression
multiple interactions

Bucladesine results in increased expression of HSD3B2 mRNA
fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HSD3B2 mRNA]

NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852

G

heat shock protein family B (small) member 1

increases expression
increases phosphorylation

Bucladesine results in increased expression of HSP27 protein
Bucladesine results in increased phosphorylation of HSPB1 protein

PMID:7541446 PMID:10559386

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

5-hydroxytryptamine receptor 1A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

islet amyloid polypeptide

increases expression

Bucladesine results in increased expression of IAPP mRNA

NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920

G

intercellular adhesion molecule 1

multiple interactions

Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression
multiple interactions

Bucladesine results in increased expression of ID1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

interferon-related developmental regulator 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA

NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194

G

insulin-like growth factor 1

multiple interactions

Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 1

increases expression
multiple interactions

Bucladesine results in increased expression of IGFBP1
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]

PMID:12093828 PMID:20823114 PMID:30328349

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein 4

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA

NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225

G

immunoglobulin heavy constant epsilon

multiple interactions

Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]

G

interleukin 10

decreases expression
multiple interactions

Bucladesine results in decreased expression of IL10
Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein]

PMID:11301049 PMID:19273625

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 13

decreases expression
decreases secretion

Bucladesine results in decreased expression of IL13 mRNA
Bucladesine results in decreased secretion of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 beta

multiple interactions

Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 23 subunit alpha

increases expression
multiple interactions

Bucladesine results in increased expression of IL23A mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA

PMID:19273625 PMID:20823114

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 2 receptor subunit alpha

decreases expression

Bucladesine results in decreased expression of IL2RA protein

PMID:1709825 PMID:25433234

NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697

G

interleukin 4

multiple interactions

Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein]

PMID:11886533 PMID:12230500

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

[Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

decreases expression
multiple interactions

Bucladesine results in decreased expression of INHA mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA]

PMID:21693180 PMID:23200735

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

insulin-like 3

multiple interactions
increases expression

[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA]

PMID:21458522 PMID:21693180 PMID:23200735

NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560

G

integrator complex subunit 7

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA

NCBI chr13:103,155,123...103,207,953
Ensembl chr13:103,155,090...103,208,592

G

interferon regulatory factor 9

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA

NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236

G

interferon stimulated exonuclease gene 20-like 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA

NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614

G

integrin subunit beta 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

inter-alpha-trypsin inhibitor heavy chain 5

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA

NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein
Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form
Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein]
[Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]

PMID:9187264 PMID:18755854 PMID:19282384 PMID:19698295 PMID:26049102

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

lysine acetyltransferase 2A

multiple interactions

Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]

NCBI chr10:85,632,216...85,640,561
Ensembl chr10:85,632,216...85,640,166

G

potassium voltage-gated channel subfamily C member 4

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA

NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233

G

kininogen 1

increases activity

Bucladesine results in increased activity of KNG1

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

keratin 8

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA]

NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728

G

laminin subunit beta 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA

NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549

G

lactate dehydrogenase A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

leptin

decreases expression

Bucladesine results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

galectin 3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

luteinizing hormone/choriogonadotropin receptor

decreases expression
multiple interactions

Bucladesine results in decreased expression of LHCGR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA]

PMID:21693180 PMID:23200735

NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521

G

lipase E, hormone sensitive type

affects localization
increases activity
increases expression
multiple interactions

Bucladesine affects the localization of LIPE protein
Bucladesine results in increased activity of LIPE protein
Bucladesine results in increased expression of LIPE mRNA
[Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]

PMID:11160373 PMID:23362264

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mucin-12-like

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MUC12 mRNA

NCBI chr12:19,486,041...19,493,995

G

lysophosphatidic acid receptor 3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA

NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357

G

latent transforming growth factor beta binding protein 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA

NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349

G

leukotriene C4 synthase

decreases secretion

Bucladesine results in decreased secretion of LTC4S protein

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

microtubule-associated protein 1A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA

NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899

G

microtubule-associated protein 2

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein
Bucladesine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]]

PMID:8526880 PMID:19282384 PMID:22875961

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein
Bucladesine results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]]

PMID:8526880 PMID:19282384 PMID:22875961

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA

NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229

G

microRNA 125a

decreases expression

Bucladesine results in decreased expression of MIR125A mRNA

NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710

G

microRNA 145

decreases expression

Bucladesine results in decreased expression of MIR145 mRNA

NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727

G

microRNA 27b

multiple interactions

[Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA

NCBI chr17:1,813,427...1,813,523
Ensembl chr17:1,813,426...1,813,529

G

microRNA 455

decreases expression

Bucladesine results in decreased expression of MIR455 mRNA

NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390

G

marker of proliferation Ki-67

decreases expression

Bucladesine results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein

PMID:7798212 PMID:9187264

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin, heavy chain 9

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA

NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457

G

myosin light chain 12A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA

NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580

G

myosin light chain 12B

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA

NCBI chr 9:110,873,855...110,888,187

G

myosin light chain kinase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

myoferlin

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA

NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334

G

neutrophil cytosolic factor 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

N-deacetylase and N-sulfotransferase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA

NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191

G

neurofilament light chain

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neurofilament medium chain

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

neurogenin 1

multiple interactions
affects expression

bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein]
Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein

NCBI chr17:8,362,878...8,364,397
Ensembl chr17:8,362,821...8,364,571

G

nexilin (F actin binding protein)

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA

NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases response to substance

[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nerve growth factor

multiple interactions

[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nucleolar protein with MIF4G domain 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA

NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709

G

nephrocystin 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA

NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234

G

neuronal pentraxin receptor

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA

NCBI chr 7:111,336,660...111,354,737
Ensembl chr 7:111,336,664...111,354,802

G

neuropeptide Y

increases expression

Bucladesine results in increased expression of NPY mRNA

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 0, group B, member 1

decreases expression
multiple interactions

Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]

PMID:18787026 PMID:19282384

NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions

NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 2, group F, member 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA

NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions
increases expression

NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein]
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]]

PMID:18787026 PMID:19282384 PMID:36565944

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

nuclear receptor subfamily 5, group A, member 1

multiple interactions
increases expression

Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 protein]
Bucladesine results in increased expression of NR5A1 mRNA; Bucladesine results in increased expression of NR5A1 protein
NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]

PMID:18184656 PMID:18787026 PMID:35987080

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

nuclear receptor interacting protein 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA

NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761

G

5' nucleotidase, ecto

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

neurotrophin 3

increases expression

Bucladesine results in increased expression of NTF3 protein

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

neurotensin

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

nucleoporin 155

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA

NCBI chr 2:57,201,310...57,252,918
Ensembl chr 2:57,201,272...57,254,148

G

ornithine decarboxylase 1

multiple interactions
decreases activity

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein]

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

opioid growth factor receptor-like 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA

NCBI chr 9:25,828,865...25,842,424
Ensembl chr 9:25,828,869...25,842,352

G

olfactory receptor family 8 subfamily B member 8

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA

NCBI chr 8:37,693,578...37,694,510
Ensembl chr 8:37,693,499...37,694,547

G

prolyl 4-hydroxylase subunit beta

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

progestagen associated endometrial protein

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA

NCBI chr 3:8,531,136...8,534,430
Ensembl chr 3:8,531,138...8,534,430

G

paralemmin A kinase anchor protein

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA

NCBI chr 5:72,536,986...72,648,524
NCBI chr 5:72,313,646...72,450,645
Ensembl chr 5:72,181,718...72,648,524

G

paired box 6

multiple interactions
affects expression

bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein]
Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

protocadherin 18

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA

NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883

G

protocadherin beta 5

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA

NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases expression

Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]
Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]

PMID:1371108 PMID:24428821

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

platelet derived growth factor subunit A

decreases expression

Bucladesine results in decreased expression of PDGFA mRNA

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

pyruvate dehydrogenase kinase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

platelet factor 4

increases expression
multiple interactions

Bucladesine results in increased expression of PF4 mRNA
[Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA

NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365

G

progesterone receptor membrane component 2

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA

NCBI chr 2:124,068,257...124,084,155
Ensembl chr 2:124,068,260...124,084,155

G

phosphatidylinositol transfer protein, cytoplasmic 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA

NCBI chr10:92,163,558...92,428,971
Ensembl chr10:92,167,196...92,429,297

G

polycystin 2 like 1, transient receptor potential cation channel

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA

NCBI chr 1:243,032,891...243,070,031
Ensembl chr 1:243,032,913...243,070,031

G

plasminogen activator, tissue type

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

pleckstrin homology and RhoGEF domain containing G3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA

NCBI chr 6:95,265,756...95,308,952
Ensembl chr 6:95,266,058...95,310,359

G

perilipin 1

increases expression
multiple interactions

Bucladesine results in increased expression of PLIN1 mRNA
LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

plastin 3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA

NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891

G

peripheral myelin protein 22

multiple interactions
increases activity

Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter]

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

patatin-like phospholipase domain containing 6

increases expression
multiple interactions

Bucladesine results in increased expression of PNPLA6 mRNA
Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734

G

proopiomelanocortin

increases expression

Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

POU class 5 homeobox 1

affects expression
multiple interactions

Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein
bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein]

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator-activated receptor gamma

increases expression
multiple interactions

Bucladesine results in increased expression of PPARG protein
[ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein
IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA]

PMID:24428821 PMID:26064446

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

peptidylprolyl isomerase A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA

NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601

G

proline rich membrane anchor 1

increases expression

Bucladesine results in increased expression of PRIMA1 mRNA

NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions
increases activity

KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

prolactin

multiple interactions

[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]]

PMID:20823114 PMID:30328349 PMID:36682589

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

serine protease 12

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA

NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

PMID:11095985 PMID:12164941 PMID:24003391

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 7

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA

NCBI chr 9:14,352,155...14,418,473
Ensembl chr 9:14,351,202...14,418,494

G

protein phosphatase 2 phosphatase activator

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA

NCBI chr 3:13,689,742...13,720,287
Ensembl chr 3:13,689,741...13,722,549

G

RAB1B, member RAS oncogene family

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA

NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868
Ensembl chr X:202,405,759...202,413,868

G

RAB31, member RAS oncogene family

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA

NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253

G

RAN, member RAS oncogene family

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA

NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276

G

RB transcriptional corepressor 1

decreases activity
decreases phosphorylation
multiple interactions

Bucladesine results in decreased activity of RB1 protein
Bucladesine results in decreased phosphorylation of RB1 protein
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]

PMID:10697531 PMID:16718685

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

renin

increases secretion
increases expression

Bucladesine results in increased secretion of REN protein
Bucladesine results in increased expression of REN mRNA

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

ret proto-oncogene

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA

NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176

G

regulator of G-protein signaling 10

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA

NCBI chr 1:182,946,334...182,987,729
Ensembl chr 1:182,946,336...182,987,697

G

Rho-related BTB domain containing 3

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA

NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041

G

Ras and Rab interactor 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA

NCBI chr 1:202,355,729...202,362,731
Ensembl chr 1:202,355,890...202,362,729

G

ribophorin I

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA

NCBI chr 4:120,543,667...120,565,069
Ensembl chr 4:120,543,667...120,565,069

G

ribosomal protein S6 kinase B1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

ribosomal protein SA

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA

NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247

G

S100 calcium binding protein A14

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA

NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423

G

store-operated calcium entry-associated regulatory factor

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA

NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545

G

secretory carrier membrane protein 4

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA

NCBI chr 7:9,101,504...9,113,929
Ensembl chr 7:9,101,489...9,113,967

G

scavenger receptor class B, member 1

multiple interactions
increases expression

LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]

PMID:23045399 PMID:23362264

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

syndecan binding protein

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA

NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572

G

selenoprotein T

multiple interactions
increases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]

NCBI chr 2:142,804,387...142,821,438
Ensembl chr 2:142,804,405...142,821,427

G

semaphorin 3A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA

NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432

G

septin 11

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA

NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853

G

stratifin

multiple interactions

[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

solute carrier family 18 member A3

increases expression
multiple interactions

Bucladesine results in increased expression of SLC18A3 protein
Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein]

NCBI chr16:7,713,630...7,716,491

G

solute carrier family 2 member 1

multiple interactions

[Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 5

multiple interactions

Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA]

NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106

G

SMAD family member 6

multiple interactions

Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA]

NCBI chr 8:64,450,114...64,519,673
Ensembl chr 8:64,450,114...64,519,763

G

superoxide dismutase 2

multiple interactions
increases expression
increases activity

Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein]

PMID:12093828 PMID:20685861

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 1

multiple interactions
affects expression

bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein]
Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein

NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762

G

sterol regulatory element binding transcription factor 2

multiple interactions
increases expression

Organophosphates inhibits the reaction [Bucladesine results in increased expression of SREBF2 mRNA]

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

serine and arginine rich splicing factor 7

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA

NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965

G

steroidogenic acute regulatory protein

multiple interactions
increases expression
decreases expression

27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]]
[IMOL S-140 co-treated with triphenyl phosphate co-treated with tris(chloroethyl)phosphate co-treated with diphenylcresyl phosphate co-treated with tert-butylphenyl diphenyl phosphate co-treated with tri-xylenyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Organophosphates inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]
Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein
Bucladesine results in decreased expression of STAR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA]

PMID:10964798 PMID:10993823 PMID:11213355 PMID:18755854 PMID:18787026 More...

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

multiple interactions

STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

serine/threonine kinase 38

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA

NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198

G

sulfatase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA

NCBI chr 5:6,362,894...6,526,174
Ensembl chr 5:6,362,911...6,525,584

G

transgelin

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA

NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668

G

transcription elongation factor A1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA

NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745
Ensembl chr15:14,631,454...14,668,745

G

telomerase reverse transcriptase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

testin gene

decreases expression
multiple interactions

Bucladesine results in decreased expression of TESTIN mRNA
Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]

NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385

G

transferrin receptor

decreases expression

Bucladesine results in decreased expression of TFRC protein

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor alpha

decreases expression

Bucladesine results in decreased expression of TGFA mRNA

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

multiple interactions

Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]

PMID:11576339 PMID:16430859

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transglutaminase 2

multiple interactions

[O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein

NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981

G

tyrosine hydroxylase

increases expression

Bucladesine results in increased expression of TH mRNA

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tight junction protein 1

multiple interactions

Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tenascin C

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA

NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624

G

tumor necrosis factor

multiple interactions

Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein]

PMID:11301049 PMID:12509806 PMID:12538815 PMID:15081246 PMID:20388727

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

tryptase gamma 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA

NCBI chr10:14,386,352...14,390,258
Ensembl chr10:14,386,352...14,390,258

G

thioredoxin 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

ubiquitin-conjugating enzyme E2D 2B

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA

NCBI chr14:1,915,999...1,917,473
Ensembl chr14:1,916,845...1,917,416

G

uncoupling protein 1

increases expression
multiple interactions

Bucladesine results in increased expression of UCP1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA]

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

UDP-glucose ceramide glucosyltransferase

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

ubiquitin specific peptidase 12

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA

NCBI chr12:8,309,845...8,363,686
Ensembl chr12:8,309,750...8,363,656

G

vascular endothelial growth factor A

increases expression

Bucladesine results in increased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions

[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

VPS39 subunit of HOPS complex

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA

NCBI chr 3:107,266,846...107,304,884
Ensembl chr 3:107,267,310...107,304,975

G

Wnt family member 5A

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

WW domain containing transcription regulator 1

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA

NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968

G

zinc finger and BTB domain containing 45

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA

NCBI chr 1:73,634,895...73,639,802
Ensembl chr 1:73,635,448...73,639,556

G

zinc finger and SCAN domain containing 10

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA

NCBI chr10:12,636,302...12,646,275
Ensembl chr10:12,636,302...12,646,275

G

zinc finger and SCAN domain containing 20

multiple interactions

[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA

NCBI chr 5:140,926,596...140,956,285
Ensembl chr 5:140,930,689...140,956,336

capsaicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression
increases response to substance

1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Capsaicin results in increased expression of ABCA1 protein]; [Capsaicin results in increased expression of ABCA1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; APOE affects the reaction [Capsaicin results in increased expression of ABCA1 protein]; Cyclosporine affects the reaction [Capsaicin results in increased expression of ABCA1 protein]; KT 5720 inhibits the reaction [Capsaicin results in increased expression of ABCA1 protein]; TRPV1 gene mutant form inhibits the reaction [Capsaicin results in increased expression of ABCA1 protein]
ABCA1 results in increased susceptibility to Capsaicin

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

increases expression
decreases expression
multiple interactions

Capsaicin results in increased expression of ABCB1 mRNA; Capsaicin results in increased expression of ABCB1 protein
Capsaicin results in decreased expression of ABCB1A mRNA
Capsaicin affects the reaction [ABCB1 protein results in increased export of Digoxin]

PMID:16674925 PMID:24013073

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

decreases expression

Capsaicin results in decreased expression of ABCB1B mRNA

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

increases expression

Capsaicin results in increased expression of ABL1 mRNA

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

acetyl-CoA carboxylase beta

decreases expression

Capsaicin results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA oxidase 1

increases expression

Capsaicin results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase long-chain family member 3

decreases expression

Capsaicin results in decreased expression of ACSL3 mRNA

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

adiponectin, C1Q and collagen domain containing

increases secretion
increases expression

Capsaicin results in increased secretion of ADIPOQ protein
Capsaicin results in increased expression of ADIPOQ mRNA; Capsaicin results in increased expression of ADIPOQ protein

PMID:17295509 PMID:17719033 PMID:19798065

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenoceptor alpha 2A

decreases response to substance

ADRA2A results in decreased susceptibility to Capsaicin

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

aspartylglucosaminidase

decreases expression

Capsaicin results in decreased expression of AGA mRNA

NCBI chr16:38,504,661...38,516,607
Ensembl chr16:38,504,663...38,516,606

G

angiotensin II receptor, type 1a

increases expression

Capsaicin results in increased expression of AGTR1A mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

aryl hydrocarbon receptor

multiple interactions

Capsaicin inhibits the reaction [Methylcholanthrene results in increased activity of and results in increased localization of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

affects localization

Capsaicin affects the localization of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

akirin 2

increases expression

Capsaicin results in increased expression of AKIRIN2 mRNA

NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568

G

aldo-keto reductase family 1 member A1

multiple interactions

Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of AKR1A1 protein]

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 7 member A3

multiple interactions

Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of AKR7A3 protein]

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

AKT serine/threonine kinase 1

increases expression
increases phosphorylation
increases activity
multiple interactions

Capsaicin results in increased expression of AKT1 protein modified form
Capsaicin results in increased phosphorylation of AKT1 protein
Capsaicin results in increased activity of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Capsaicin co-treated with Oxygen deficiency co-treated with Oxygen] results in increased phosphorylation of AKT1 protein]; [Capsaicin co-treated with Oxygen deficiency co-treated with Oxygen] results in increased phosphorylation of AKT1 protein
[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein; EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of AKT1 protein]; capsazepine inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]

PMID:16360265 PMID:17084039 PMID:17979524 PMID:19011674 PMID:19059400 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

increases expression

Capsaicin results in increased expression of ALB protein

PMID:9537786 PMID:18991268

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 3 family, member A1

decreases expression

Capsaicin results in decreased expression of ALDH3A1 mRNA

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

arachidonate 5-lipoxygenase

multiple interactions
decreases activity

[Capsaicin co-treated with Curcumin] results in decreased activity of ALOX5 protein
Capsaicin results in decreased activity of ALOX5 protein

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

anti-Mullerian hormone receptor type 2

decreases expression

Capsaicin results in decreased expression of AMHR2 mRNA

NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258

G

amnion associated transmembrane protein

multiple interactions
increases expression

AMN protein inhibits the reaction [Capsaicin results in increased expression of SST protein]; AMN protein inhibits the reaction [Capsaicin results in increased expression of TAC1 protein]
Capsaicin results in increased expression of AMN protein

NCBI chr 6:130,311,372...130,318,815
Ensembl chr 6:130,311,372...130,318,815

G

angiopoietin 1

increases expression

Capsaicin results in increased expression of ANGPT1 mRNA

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

increases expression

Capsaicin results in increased expression of ANGPT2 mRNA

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

apoptotic peptidase activating factor 1

increases expression

Capsaicin results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

apolipoprotein B

increases expression

Capsaicin results in increased expression of APOB mRNA

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C1

decreases expression

Capsaicin results in decreased expression of APOC1 mRNA

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

apolipoprotein E

multiple interactions

APOE affects the reaction [Capsaicin results in decreased expression of LRP1 protein]; APOE affects the reaction [Capsaicin results in increased expression of ABCA1 protein]; Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]; Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Triglycerides]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

aquaporin 1

increases response to substance

AQP1 results in increased susceptibility to Capsaicin

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

androgen receptor

increases expression
multiple interactions

Capsaicin results in increased expression of AR protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased expression of AR protein]; Capsaicin inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Capsaicin inhibits the reaction [Dihydrotestosterone results in increased expression of AR protein]; capsazepine inhibits the reaction [Capsaicin results in increased expression of AR protein]; iodoresiniferatoxin inhibits the reaction [Capsaicin results in increased expression of AR protein]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [Capsaicin results in increased expression of AR protein]

PMID:16540674 PMID:19059400

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

multiple interactions

[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA; EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA]

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

cAMP-regulated phosphoprotein 19

increases expression

Capsaicin results in increased expression of ARPP19 mRNA

NCBI chr 8:75,779,640...75,802,474
Ensembl chr 8:75,779,523...75,802,452
Ensembl chr 8:75,779,523...75,802,452

G

arrestin domain containing 4

decreases expression

Capsaicin results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

activating transcription factor 3

multiple interactions

ATF3 mutant form inhibits the reaction [Capsaicin results in increased expression of GDF15 mRNA]; Capsaicin promotes the reaction [CEBPB protein binds to ATF3 protein binds to GSK3B protein]

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions
affects localization
increases expression

Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein]
Capsaicin affects the localization of ATF4 protein

PMID:18533110 PMID:19139269 PMID:20925121

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

autophagy related 16-like 1

decreases expression

Capsaicin results in decreased expression of ATG16L1 mRNA

NCBI chr 9:88,420,737...88,457,530
Ensembl chr 9:88,422,038...88,457,529

G

autophagy related 5

multiple interactions
increases expression

ATG5 mutant form inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein]; ATG5 mutant form inhibits the reaction [Capsaicin results in increased phosphorylation of PRKDC protein]
Capsaicin results in increased expression of ATG5 protein

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

ATM serine/threonine kinase

increases activity
multiple interactions
increases phosphorylation
increases expression

Capsaicin results in increased activity of ATM protein
3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein]; ATG5 mutant form inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein]; Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein
Capsaicin results in increased phosphorylation of ATM protein
Capsaicin results in increased expression of ATM mRNA

PMID:19502594 PMID:22226932

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

affects metabolic processing
decreases expression

Capsaicin affects the metabolism of ATP2A2 protein
Capsaicin results in decreased expression of ATP2A2 protein modified form

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATPase H+ transporting accessory protein 1

decreases expression

Capsaicin results in decreased expression of ATP6AP1 mRNA

NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034

G

BCL2-associated agonist of cell death

increases expression

Capsaicin results in increased expression of BAD mRNA

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BAG cochaperone 3

increases expression

Capsaicin results in increased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BCL2-antagonist/killer 1

increases activity
increases expression

Capsaicin results in increased activity of BAK1 protein
Capsaicin results in increased expression of BAK1 mRNA

PMID:17295509 PMID:19502594

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects expression
increases expression
affects localization
increases activity

TP53 protein promotes the reaction [Capsaicin results in increased expression of BAX protein]; TRPV6 protein promotes the reaction [Capsaicin results in increased expression of BAX protein]
Capsaicin affects the expression of BAX protein
Capsaicin results in increased expression of BAX; Capsaicin results in increased expression of BAX mRNA; Capsaicin results in increased expression of BAX protein
Capsaicin affects the localization of BAX protein
Capsaicin results in increased activity of BAX protein

PMID:16540674 PMID:17292493 PMID:17295509 PMID:19002586 PMID:19331147 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

brevican

decreases expression

Capsaicin results in decreased expression of BCAN mRNA

NCBI chr 2:173,454,479...173,467,717
Ensembl chr 2:173,454,482...173,467,460

G

BCL10, immune signaling adaptor

increases expression

Capsaicin results in increased expression of BCL10 mRNA

NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523

G

BCL2, apoptosis regulator

decreases response to substance
affects expression
increases expression
decreases expression

BCL2 protein results in decreased susceptibility to Capsaicin
Capsaicin affects the expression of BCL2 protein
Capsaicin results in increased expression of BCL2 mRNA
Capsaicin results in decreased expression of BCL2 protein
Capsaicin results in decreased expression of BCL2; Capsaicin results in decreased expression of BCL2 protein

PMID:9580328 PMID:11275362 PMID:15595419 PMID:17295509 PMID:17306913 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression
increases expression

Capsaicin results in decreased expression of BCL2L1 protein
Capsaicin results in increased expression of BCL2L1 mRNA

PMID:17505005 PMID:19502594

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

BCL2-associated transcription factor 1

increases expression

Capsaicin results in increased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

bradykinin receptor B1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Capsaicin results in increased expression of BDKRB1 mRNA]; capsazepine inhibits the reaction [Capsaicin results in increased expression of BDKRB1 mRNA]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [Capsaicin results in increased expression of BDKRB1 mRNA]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

multiple interactions

Capsaicin inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]
BDKRB2 affects the reaction [Capsaicin results in increased activity of TRPV1 protein]; BDKRB2 affects the reaction [KNG1 protein promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]]

PMID:15363968 PMID:17347322

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

brain-derived neurotrophic factor

multiple interactions
affects expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of BDNF protein]; Naproxen inhibits the reaction [Capsaicin affects the expression of BDNF protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

increases expression

Capsaicin results in increased expression of BECN1 mRNA

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BH3 interacting domain death agonist

increases cleavage
multiple interactions
increases expression

Capsaicin results in increased cleavage of BID protein
Capsaicin promotes the reaction [TNFSF10 results in increased cleavage of BID protein]
Capsaicin results in increased expression of BID mRNA

PMID:19502594 PMID:22200406

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 2

increases expression

Capsaicin results in increased expression of BIRC2 mRNA

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 5

decreases expression
multiple interactions

Capsaicin results in decreased expression of BIRC5; Capsaicin results in decreased expression of BIRC5 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Capsaicin results in decreased expression of BIRC5 protein]; BIRC5 results in decreased activity of [Capsaicin co-treated with TNFSF10 protein]

PMID:17505005 PMID:19002586 PMID:19939880

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BCL2 interacting protein 2

increases expression

Capsaicin results in increased expression of BNIP2 mRNA

NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590

G

BCL2 interacting protein 3

decreases expression
increases expression

Capsaicin results in decreased expression of BNIP3 mRNA
Capsaicin results in increased expression of BNIP3 mRNA

PMID:19502594 PMID:36044967

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

decreases expression
increases expression

Capsaicin results in decreased expression of BNIP3L mRNA
Capsaicin results in increased expression of BNIP3L mRNA

PMID:19502594 PMID:36044967

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

calcium voltage-gated channel auxiliary subunit gamma 3

decreases expression

Capsaicin results in decreased expression of CACNG3 mRNA

NCBI chr 1:177,201,361...177,297,019
Ensembl chr 1:177,201,288...177,297,024

G

calcitonin-related polypeptide alpha

increases expression
increases secretion
decreases expression
multiple interactions
affects response to substance

Capsaicin results in increased expression of CALCA mRNA; Capsaicin results in increased expression of CALCA protein
Capsaicin results in increased secretion of CALCA protein
Capsaicin results in decreased expression of CALCA mRNA; Capsaicin results in decreased expression of CALCA protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; [Capsaicin co-treated with Calcium] results in increased secretion of CALCA protein; [Capsaicin co-treated with NGF protein] results in increased secretion of CALCA protein; [Capsaicin results in decreased susceptibility to safranal] which results in decreased secretion of CALCA protein; botulinum toxin type D inhibits the reaction [[Capsaicin co-treated with Calcium] results in increased secretion of CALCA protein]; butaprost promotes the reaction [Capsaicin results in increased secretion of CALCA protein]; Calcium affects the reaction [Capsaicin inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]]; Calcium affects the reaction [Capsaicin inhibits the reaction [mustard oil results in increased secretion of CALCA protein]]; Calcium affects the reaction [mustard oil inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]]; Capsaicin inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Capsaicin inhibits the reaction [Freund's Adjuvant results in increased expression of CALCA mRNA]; Capsaicin inhibits the reaction [monophosphoryl lipid A results in increased expression of CALCA mRNA]; Capsaicin inhibits the reaction [mustard oil results in increased secretion of CALCA protein]; Capsaicin inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA]; Capsaicin promotes the reaction [Phenol results in decreased expression of CALCA protein]; Capsaicin results in increased secretion of [CALCA protein co-treated with CALCB protein]; capsazepine inhibits the reaction [Capsaicin results in increased expression of CALCA protein]; capsazepine inhibits the reaction [Capsaicin results in increased secretion of [CALCA protein co-treated with CALCB protein]]; capsazepine inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Carbon Dioxide inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; chelerythrine inhibits the reaction [Capsaicin results in increased expression of CALCA protein]; Dinoprostone promotes the reaction [Capsaicin results in increased secretion of CALCA protein]; Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; epothilone B affects the reaction [[Capsaicin co-treated with NGF protein] results in increased secretion of CALCA protein]; iodoresiniferatoxin inhibits the reaction [Capsaicin results in increased expression of CALCA protein]; mustard oil inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Nefopam inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; neuropeptide Y, Leu(31)-Pro(34)- inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; NGF protein promotes the reaction [Capsaicin results in increased expression of CALCA protein]; nociceptin (1-13) amide inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; OPRL1 protein promotes the reaction [nociceptin (1-13) amide inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]]; Paclitaxel inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Plant Extracts inhibits the reaction [Capsaicin results in decreased expression of CALCA protein]; Plant Extracts inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Polyphenols inhibits the reaction [Capsaicin results in decreased expression of CALCA protein]; Polyphenols inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; PPP3CA protein affects the reaction [mustard oil inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]]; TRPV1 protein affects the reaction [Capsaicin results in increased secretion of CALCA protein]
CALCA protein alternative form inhibits the reaction [Capsaicin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; capsazepine inhibits the reaction [Capsaicin results in increased expression of CALCA mRNA]
CALCA protein affects the susceptibility to Capsaicin
[Capsaicin co-treated with Ethanol] results in increased expression of CALCA protein; CALCA protein affects the reaction [Capsaicin results in decreased susceptibility to Ethanol]; CALCA protein affects the reaction [Capsaicin results in increased expression of IGF1 mRNA]; CALCA protein affects the reaction [Capsaicin results in increased expression of IGF1 protein]; CALCA protein affects the reaction [TRPV1 protein results in increased susceptibility to Capsaicin]; CNR1 protein affects the reaction [Capsaicin results in increased secretion of CALCA protein]; rimabotulinumtoxinB inhibits the reaction [[Capsaicin co-treated with Calcium] results in increased secretion of CALCA protein]

PMID:2462184 PMID:3412491 PMID:7473211 PMID:8971780 PMID:11738242 More...

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcitonin-related polypeptide, beta

increases expression
decreases activity
multiple interactions
increases secretion

Capsaicin results in increased expression of CALCB mRNA
CALCB protein alternative form results in decreased activity of Capsaicin
Capsaicin results in increased secretion of [CALCA protein co-treated with CALCB protein]; capsazepine inhibits the reaction [Capsaicin results in increased secretion of [CALCA protein co-treated with CALCB protein]]
capsazepine inhibits the reaction [Capsaicin results in increased expression of CALCB mRNA]
Capsaicin results in increased secretion of CALCB protein

PMID:9932722 PMID:14764656 PMID:17434803 PMID:18584893

NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125

G

calcium/calmodulin-dependent protein kinase II alpha

multiple interactions

Capsaicin results in increased phosphorylation of and results in increased expression of CAMK2A protein

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

cathelicidin antimicrobial peptide

increases expression
multiple interactions

Capsaicin results in increased expression of CAMP protein
Glyoxal promotes the reaction [Capsaicin results in increased expression of CAMP protein]

NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543

G

caspase 2

multiple interactions

[Capsaicin co-treated with TNFSF10 protein] results in increased cleavage of CASP2 protein

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

increases expression
affects cleavage
affects activity
increases activity
multiple interactions
increases cleavage
affects expression

Capsaicin results in increased expression of CASP3 protein
Capsaicin affects the cleavage of CASP3 protein
Capsaicin affects the activity of CASP3 protein
Capsaicin results in increased activity of CASP3 protein
Capsaicin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased activity of CASP3 protein]
Capsaicin results in increased cleavage of CASP3 protein
[ND1 gene mutant form results in increased susceptibility to Capsaicin] which results in increased activity of CASP3 protein; Capsaicin promotes the reaction [resveratrol results in increased activity of CASP3 protein]; Capsaicin promotes the reaction [TNFSF10 protein results in increased cleavage of CASP3 protein]; Capsaicin promotes the reaction [TNFSF10 results in increased activity of CASP3 protein]; Capsaicin promotes the reaction [TRPV1 protein results in increased activity of CASP3 protein]; Capsaicin results in increased cleavage of and results in increased activity of CASP3 protein; capsazepine inhibits the reaction [Capsaicin results in increased cleavage of and results in increased activity of CASP3 protein]; CAT protein inhibits the reaction [Capsaicin results in increased cleavage of CASP3 protein]; EUK-134 inhibits the reaction [Capsaicin results in increased cleavage of CASP3 protein]; resveratrol promotes the reaction [Capsaicin results in increased activity of CASP3 protein]
Capsaicin affects the expression of CASP3 protein

PMID:11275362 PMID:16125681 PMID:16477149 PMID:17295509 PMID:17306913 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 4

increases activity
multiple interactions
increases expression

Capsaicin results in increased activity of CASP4 protein
Capsaicin results in increased cleavage of and results in increased activity of CASP4 protein
Capsaicin results in increased expression of CASP4 mRNA

PMID:19139269 PMID:19699254 PMID:20349343 PMID:20371669

NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092

G

caspase 6

multiple interactions

[Capsaicin co-treated with TNFSF10 protein] results in increased cleavage of CASP6 protein

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions
increases activity

[Capsaicin co-treated with TNFSF10 protein] results in increased cleavage of CASP7 protein
Capsaicin results in increased activity of CASP7 protein

PMID:19139269 PMID:19699254 PMID:19855437 PMID:19939880

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity
decreases expression
multiple interactions
increases expression

Capsaicin results in increased activity of CASP8 protein
Capsaicin results in decreased expression of CASP8 protein
[Capsaicin co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; Capsaicin promotes the reaction [resveratrol results in decreased expression of CASP8 protein]; Capsaicin promotes the reaction [TNFSF10 results in increased activity of CASP8 protein]; resveratrol promotes the reaction [Capsaicin results in decreased expression of CASP8 protein]
Capsaicin results in increased expression of CASP8 mRNA

PMID:19502594 PMID:19846903 PMID:19939880 PMID:22200406

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases cleavage
increases activity
multiple interactions
increases expression
affects expression

Capsaicin results in increased cleavage of CASP9 protein
Capsaicin results in increased activity of CASP9 protein
[Capsaicin co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; Capsaicin promotes the reaction [TNFSF10 results in increased activity of CASP9 protein]; CAT protein inhibits the reaction [Capsaicin results in increased cleavage of CASP9 protein]; EUK-134 inhibits the reaction [Capsaicin results in increased cleavage of CASP9 protein]
Capsaicin results in increased expression of CASP9 protein
Capsaicin affects the expression of CASP9 protein
Capsaicin results in increased expression of CASP9 mRNA

PMID:16125681 PMID:16477149 PMID:19502594 PMID:19699254 PMID:19855437 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

CAT protein inhibits the reaction [Capsaicin results in increased cleavage of CASP3 protein]; CAT protein inhibits the reaction [Capsaicin results in increased cleavage of CASP9 protein]; CAT protein inhibits the reaction [Capsaicin results in increased phosphorylation of TP53 protein]
Capsaicin inhibits the reaction [Benzo(a)pyrene results in decreased activity of CAT protein]; Capsaicin inhibits the reaction [Benzo(a)pyrene results in decreased expression of CAT]

PMID:14871840 PMID:18023135 PMID:18338764 PMID:21647434

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

multiple interactions

[Capsaicin co-treated with CCK protein alternative form] results in increased expression of TAC1 protein; Capsaicin inhibits the reaction [CCK protein alternative form results in decreased expression of NGF mRNA]; Capsaicin promotes the reaction [CCK protein alternative form results in increased expression of NGF protein]
Capsaicin inhibits the reaction [CCK protein results in increased phosphorylation of MAPK1 protein]; Capsaicin inhibits the reaction [CCK protein results in increased phosphorylation of MAPK3 protein]

PMID:10683199 PMID:22508518

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

C-C motif chemokine ligand 19

increases expression

Capsaicin results in increased expression of CCL19 mRNA

NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308

G

C-C motif chemokine ligand 2

multiple interactions
decreases expression
decreases secretion
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL2 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CCL2 protein]; Sumatriptan affects the reaction [Capsaicin results in increased expression of CCL2 protein]
Capsaicin promotes the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]
Capsaicin results in decreased expression of CCL2 mRNA; Capsaicin results in decreased expression of CCL2 protein
Capsaicin results in decreased secretion of CCL2 protein
capsazepine inhibits the reaction [Capsaicin results in decreased secretion of CCL2 protein]; troglitazone promotes the reaction [Capsaicin results in decreased secretion of CCL2 protein]
Capsaicin results in increased expression of CCL2 mRNA; Capsaicin results in increased expression of CCL2 protein

PMID:17719033 PMID:19798065 PMID:20349343 PMID:22150557 PMID:30244119

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression
multiple interactions

Capsaicin results in increased expression of CCL20 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL20 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CCL20 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCL20 protein]

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 22

multiple interactions
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL22 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CCL22 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCL22 protein]

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

Capsaicin inhibits the reaction [Palmitic Acid results in increased expression of CCL3 mRNA]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [Capsaicin inhibits the reaction [Palmitic Acid results in increased expression of CCL3 mRNA]]
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL3 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CCL3 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCL3 protein]

PMID:21745629 PMID:22150557

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cyclin A2

decreases expression

Capsaicin results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

Capsaicin results in decreased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

Capsaicin results in decreased expression of CCND1 protein

PMID:17505005 PMID:19855437

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin L1

increases expression

Capsaicin results in increased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

C-C motif chemokine receptor 4

increases expression
multiple interactions

Capsaicin results in increased expression of CCR4 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCR4 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CCR4 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCR4 protein]

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

CD46 molecule

increases expression

Capsaicin results in increased expression of CD46 mRNA

NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445

G

Cd68 molecule

decreases expression

Capsaicin results in decreased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

Cd80 molecule

increases expression
multiple interactions

Capsaicin results in increased expression of CD80 protein
[Naproxen co-treated with Sumatriptan] affects the reaction [Capsaicin results in increased expression of CD80 protein]; Naproxen affects the reaction [Capsaicin results in increased expression of CD80 protein]; Sumatriptan affects the reaction [Capsaicin results in increased expression of CD80 protein]

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CD8 subunit beta

increases expression

Capsaicin results in increased expression of CD8B mRNA

NCBI chr 4:103,312,596...103,328,523
Ensembl chr 4:103,312,578...103,328,553

G

cell division cycle 14A

increases expression

Capsaicin results in increased expression of CDC14A mRNA

NCBI chr 2:204,225,540...204,380,927
Ensembl chr 2:204,225,540...204,380,927

G

cadherin 1

increases expression
multiple interactions

Capsaicin results in increased expression of CDH1 protein
acadesine promotes the reaction [Capsaicin results in increased expression of CDH1 protein]; bafilomycin A1 inhibits the reaction [Capsaicin results in increased expression of CDH1 protein]; dorsomorphin inhibits the reaction [Capsaicin results in increased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions
decreases expression

acadesine promotes the reaction [Capsaicin results in decreased expression of CDH2 protein]; bafilomycin A1 inhibits the reaction [Capsaicin results in decreased expression of CDH2 protein]; dorsomorphin inhibits the reaction [Capsaicin results in decreased expression of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin-dependent kinase 1

increases expression

Capsaicin results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

decreases expression

Capsaicin results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Capsaicin results in decreased expression of CDK4 mRNA

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
decreases expression

Capsaicin results in increased expression of CDKN1A mRNA; Capsaicin results in increased expression of CDKN1A protein
Capsaicin results in decreased expression of CDKN1A protein

PMID:16540674 PMID:19502594 PMID:20646592 PMID:22226932

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression
decreases expression

Capsaicin results in increased expression of CDKN1B
Capsaicin results in increased expression of CDKN1B protein
Capsaicin results in decreased expression of CDKN1B protein

PMID:19855437 PMID:20069556 PMID:22226932

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

increases expression

Capsaicin results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

CCAAT/enhancer binding protein alpha

decreases expression
multiple interactions

Capsaicin results in decreased expression of CEBPA protein
Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of CEBPA mRNA]

PMID:17295509 PMID:20359164

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions
increases activity

[CEBPB protein binds to GDF15 promoter] promotes the reaction [Capsaicin results in increased expression of GDF15 mRNA]; Capsaicin promotes the reaction [CEBPB protein binds to ATF3 protein binds to GSK3B protein]; CEBPB mutant form inhibits the reaction [Capsaicin results in increased expression of GDF15 mRNA]; CEBPB protein promotes the reaction [Capsaicin results in increased expression of GDF15 mRNA]
Capsaicin results in increased activity of CEBPB protein
[Capsaicin results in increased activity of CEBPB protein] inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; [Capsaicin results in increased activity of CEBPB protein] inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 protein]

PMID:20110283 PMID:21250977

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

cofilin 1

multiple interactions

[Capsaicin results in decreased phosphorylation of and results in increased activity of CFL1 protein] which results in increased import of Calcium; Capsaicin results in decreased phosphorylation of and results in increased activity of CFL1 protein; Egtazic Acid inhibits the reaction [Capsaicin results in decreased phosphorylation of and results in increased activity of CFL1 protein]

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

CASP8 and FADD-like apoptosis regulator

increases expression
decreases expression

Capsaicin results in increased expression of CFLAR mRNA
Capsaicin results in decreased expression of CFLAR protein alternative form

PMID:19502594 PMID:19939880

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

CF transmembrane conductance regulator

increases activity

Capsaicin results in increased activity of CFTR protein; Capsaicin results in increased activity of CFTR protein mutant form

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

checkpoint kinase 2

increases expression

Capsaicin results in increased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

class II, major histocompatibility complex, transactivator

multiple interactions

Capsaicin inhibits the reaction [IFNG protein results in increased expression of CIITA mRNA]

NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440

G

ciliogenesis associated kinase 1

increases expression
multiple interactions

Capsaicin results in increased expression of CILK1 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CILK1 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CILK1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CILK1 protein]

NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691

G

claudin 1

increases expression

Capsaicin results in increased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

C-type lectin domain family 2, member D

decreases expression

Capsaicin results in decreased expression of CLEC2D mRNA

NCBI chr 4:162,216,052...162,239,530
Ensembl chr 4:162,216,572...162,239,527

G

CDC-like kinase 1

increases expression

Capsaicin results in increased expression of CLK1 mRNA

NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000

G

cannabinoid receptor 1

multiple interactions
increases activity
affects response to substance

CNR1 protein affects the reaction [Capsaicin results in increased secretion of CALCA protein]
Capsaicin results in increased activity of CNR1 protein
CNR1 protein affects the susceptibility to Capsaicin

PMID:11408034 PMID:18987195

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

ciliary neurotrophic factor

increases expression
multiple interactions

Capsaicin results in increased expression of CNTF protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CNTF protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CNTF protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CNTF protein]

NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877

G

ciliary neurotrophic factor receptor

multiple interactions
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CNTFR protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CNTFR protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CNTFR protein]

NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392

G

collagen type XVIII alpha 1 chain

increases expression

Capsaicin results in increased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

collagen type I alpha 1 chain

increases expression

Capsaicin results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

increases expression

Capsaicin results in increased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

cytochrome c oxidase subunit 4i1

increases expression

Capsaicin results in increased expression of COX4I1 protein

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

cytochrome c oxidase subunit 5A

increases expression

Capsaicin results in increased expression of COX5A protein

NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781

G

cytochrome c oxidase subunit 6A1

increases expression

Capsaicin results in increased expression of COX6A1 mRNA

NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041

G

carnitine palmitoyltransferase 1A

multiple interactions
increases expression

Capsaicin promotes the reaction [Palmitic Acid results in increased expression of CPT1A mRNA]
Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]
Capsaicin results in increased expression of CPT1A mRNA

PMID:20359164 PMID:21745629

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

multiple interactions
increases phosphorylation

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; KN 93 inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; NPC 15437 inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; Ro 31-8425 inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]

PMID:15385614 PMID:15631885 PMID:16159392

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

colony stimulating factor 2

increases expression
multiple interactions

Capsaicin results in increased expression of CSF2 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CSF2 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CSF2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CSF2 protein]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

casein kinase 2 alpha 1

increases phosphorylation

Capsaicin results in increased phosphorylation of CSNK2A1 protein

NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696

G

casein kinase 2 beta

increases phosphorylation

Capsaicin results in increased phosphorylation of CSNK2B protein

NCBI chr20:3,700,363...3,705,331
Ensembl chr20:3,698,733...3,707,133

G

catenin beta 1

increases expression
multiple interactions

Capsaicin results in increased expression of CTNNB1 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CTNNB1 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CTNNB1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X3-C motif chemokine ligand 1

affects expression
multiple interactions

Capsaicin affects the expression of CX3CL1 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of CX3CL1 protein]; Naproxen inhibits the reaction [Capsaicin affects the expression of CX3CL1 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of CX3CL1 protein]

NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 10

increases expression
multiple interactions

Capsaicin results in increased expression of CXCL10 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCL10 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CXCL10 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCL10 protein]

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

Capsaicin results in increased expression of CXCL2 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCL2 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CXCL2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine receptor 4

increases expression
multiple interactions

Capsaicin results in increased expression of CXCR4 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCR4 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of CXCR4 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCR4 protein]

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome b-245 beta chain

multiple interactions

CYBB protein affects the reaction [TRPV1 protein results in increased susceptibility to Capsaicin]
CYBB mutant form inhibits the reaction [Capsaicin results in increased expression of STAT1 protein]

PMID:18203709 PMID:20712533

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
affects expression

[Capsaicin results in increased activity of CEBPB protein] inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; [Capsaicin results in increased activity of CEBPB protein] inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 protein]; Capsaicin affects the expression of and affects the activity of CYP1A1 protein; Capsaicin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; Capsaicin inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Capsaicin inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 protein]
Capsaicin affects the expression of CYP1A1 mRNA

PMID:19449198 PMID:21250977

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

Capsaicin results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily a, polypeptide 2

decreases expression

Capsaicin results in decreased expression of CYP2A2 mRNA

NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

Capsaicin results in decreased activity of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity

Capsaicin results in decreased activity of CYP2D6 protein

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

Capsaicin results in increased expression of CYP2E1

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
decreases activity

Capsaicin results in decreased expression of CYP3A2 mRNA; Capsaicin results in decreased expression of CYP3A2 protein
Capsaicin results in decreased activity of CYP3A4 protein

PMID:20388821 PMID:24013073

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

decreases expression

Capsaicin results in decreased expression of CYP3A23-3A1 mRNA; Capsaicin results in decreased expression of CYP3A23-3A1 protein

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

death-associated protein

increases expression

Capsaicin results in increased expression of DAP mRNA

NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752

G

DNA-damage inducible transcript 3

increases expression
affects localization

Capsaicin results in increased expression of DDIT3 protein
Capsaicin affects the localization of DDIT3 protein
Capsaicin analog results in increased expression of DDIT3 mRNA; Capsaicin results in increased expression of DDIT3; Capsaicin results in increased expression of DDIT3 mRNA; Capsaicin results in increased expression of DDIT3 protein

PMID:18533110 PMID:19139269 PMID:19285962 PMID:19331147 PMID:19699254 More...

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

defensin beta 2

multiple interactions
increases expression

Glyoxal promotes the reaction [Capsaicin results in increased expression of DEFB2 protein]

NCBI chr16:70,231,870...70,245,817
Ensembl chr16:70,231,945...70,245,784

G

DEPP autophagy regulator 1

increases expression

Capsaicin results in increased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

DNA fragmentation factor subunit alpha

decreases expression

Capsaicin results in decreased expression of DFFA

NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633

G

dipeptidylpeptidase 3

decreases expression

Capsaicin results in decreased expression of DPP3 mRNA

NCBI chr 1:202,204,683...202,228,501
Ensembl chr 1:202,204,693...202,228,541

G

dual specificity phosphatase 1

multiple interactions

[NFKB1 mutant form inhibits the reaction [Capsaicin results in increased expression of PRKCD protein]] which results in increased expression of DUSP1 protein; DUSP1 mutant form promotes the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; DUSP1 mutant form promotes the reaction [Capsaicin results in increased secretion of CXCL8 protein]; DUSP1 mutant form promotes the reaction [Capsaicin results in increased secretion of IL6 protein]

NCBI chr10:16,680,478...16,683,275

G

E2F transcription factor 1

increases expression

Capsaicin results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin 1

decreases activity
multiple interactions

EDN1 protein results in decreased activity of Capsaicin
EDN1 protein promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]; FR 139317 inhibits the reaction [EDN1 protein results in decreased activity of Capsaicin]

PMID:9932722 PMID:19429182

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

eukaryotic translation elongation factor 2

multiple interactions

Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of EEF2 protein]

NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183

G

epidermal growth factor

multiple interactions
decreases expression
decreases activity

Capsaicin inhibits the reaction [EGF results in increased activity of MMP2 protein]; Capsaicin inhibits the reaction [EGF results in increased activity of MMP9 protein]; Capsaicin inhibits the reaction [EGF results in increased expression of MMP14]; Capsaicin inhibits the reaction [EGF results in increased expression of MMP2]; Capsaicin inhibits the reaction [EGF results in increased expression of MMP9]; Capsaicin inhibits the reaction [EGF results in increased localization of FOS protein]; Capsaicin inhibits the reaction [EGF results in increased localization of JUN protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of AKT1 protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of MAPK1 protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of MAPK3 protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of MAPK8 protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of MAPK9 protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of PTK2 protein]
Capsaicin results in decreased expression of EGF protein
Capsaicin results in decreased activity of EGF protein

PMID:9324159 PMID:14521749 PMID:21462327

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
decreases expression
increases phosphorylation

AG 1879 inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]; Capsaicin inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]
Capsaicin results in decreased expression of EGFR protein
[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein; AG 1879 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]; EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of AREG mRNA]; EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of AKT1 protein]; EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein]; EGFR gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein]; EGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]]; EGFR gene mutant form inhibits the reaction [Capsaicin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]]; EGFR gene mutant form inhibits the reaction [Capsaicin results in increased expression of PTGS2 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]

PMID:14521749 PMID:19855437 PMID:20619260 PMID:20660715 PMID:21462327

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

increases expression

Capsaicin results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 2A

increases phosphorylation

Capsaicin results in increased phosphorylation of EIF2A protein

PMID:18533110 PMID:19285962

NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

Capsaicin results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

elastin

increases expression

Capsaicin results in increased expression of ELN mRNA

NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928

G

enolase 2

multiple interactions

Capsaicin inhibits the reaction [Benzo(a)pyrene results in increased expression of ENO2 protein]

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

ecto-NOX disulfide-thiol exchanger 2

increases response to substance

ENOX2 results in increased susceptibility to Capsaicin

NCBI chr X:128,270,941...128,593,074
Ensembl chr X:128,271,074...128,593,039

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

erythropoietin receptor

increases expression

Capsaicin results in increased expression of EPOR mRNA; Capsaicin results in increased expression of EPOR protein

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

erb-b2 receptor tyrosine kinase 2

affects expression
decreases expression

Capsaicin affects the expression of ERBB2 mRNA
Capsaicin results in decreased expression of ERBB2 protein

PMID:19502594 PMID:19855437

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

endoplasmic reticulum to nucleus signaling 1

increases expression

Capsaicin results in increased expression of ERN1 protein

PMID:19139269 PMID:19699254

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ERBB receptor feedback inhibitor 1

multiple interactions
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of ERRFI1 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of ERRFI1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of ERRFI1 protein]

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

electron transfer flavoprotein subunit alpha

multiple interactions

Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of ETFA protein]

NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969

G

exosome component 8

decreases expression

Capsaicin results in decreased expression of EXOSC8 mRNA

NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928

G

coagulation factor II, thrombin

affects expression

Capsaicin affects the expression of F2 protein

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

F2R like trypsin receptor 1

multiple interactions

F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]; PRKCE protein affects the reaction [F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]]

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

fatty acid binding protein 4

decreases expression
multiple interactions

Capsaicin results in decreased expression of FABP4 mRNA
Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of FABP4 mRNA]; Capsaicin inhibits the reaction [Dietary Fats results in increased expression of FABP4 protein]

PMID:18533110 PMID:20359164

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid binding protein 5

decreases expression

Capsaicin results in decreased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

Fas associated via death domain

increases expression
multiple interactions

Capsaicin results in increased expression of FADD protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FADD protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of FADD protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FADD protein]

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

family with sequence similarity 162, member A

decreases expression

Capsaicin results in decreased expression of FAM162A mRNA

NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239

G

Fas cell surface death receptor

increases expression
multiple interactions
affects expression

Capsaicin results in increased expression of FAS mRNA; Capsaicin results in increased expression of FAS protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FAS protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of FAS protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FAS protein]
Capsaicin promotes the reaction [resveratrol results in increased expression of FAS protein]
Capsaicin affects the expression of FAS mRNA

PMID:19502594 PMID:19846903 PMID:21310942 PMID:22150557

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FASLG protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of FASLG protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

F-box and leucine-rich repeat protein 2

increases expression

Capsaicin results in increased expression of FBXL2 mRNA

NCBI chr 8:113,916,660...113,965,137
Ensembl chr 8:113,913,373...113,965,066

G

farnesyl diphosphate farnesyl transferase 1

increases expression

Capsaicin results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

increases expression

Capsaicin results in increased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor 2

decreases expression

Capsaicin results in decreased expression of FGF2 protein

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor binding protein 1

multiple interactions
affects expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of FGFBP1 protein]; Naproxen inhibits the reaction [Capsaicin affects the expression of FGFBP1 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of FGFBP1 protein]

NCBI chr14:67,103,686...67,107,492
Ensembl chr14:67,104,545...67,107,496

G

Fibroblast growth factor receptor 1

decreases expression

Capsaicin results in decreased expression of FGFR1 protein

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibrinogen-like 1

multiple interactions
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FGL1 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of FGL1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FGL1 protein]

NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093

G

FKBP prolyl isomerase 4

decreases expression

Capsaicin results in decreased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

folliculin

increases expression

Capsaicin results in increased expression of FLCN mRNA

NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769

G

fibromodulin

increases expression

Capsaicin results in increased expression of FMOD mRNA

NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133

G

farnesyltransferase, CAAX box, subunit alpha

increases expression

Capsaicin results in increased expression of FNTA mRNA

NCBI chr16:66,065,131...66,083,460
Ensembl chr16:66,065,132...66,083,460

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression
increases expression
multiple interactions

Capsaicin results in decreased expression of FOS mRNA
Capsaicin results in increased expression of FOS protein
Capsaicin results in increased expression of FOS; Capsaicin results in increased expression of FOS mRNA; Capsaicin results in increased expression of FOS protein
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline inhibits the reaction [Capsaicin results in increased expression of FOS]; 2-amino-4-phosphonobutyric acid inhibits the reaction [Capsaicin results in increased expression of FOS]; 6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Capsaicin results in increased expression of FOS]; Capsaicin inhibits the reaction [8-sulfocholecystokinin octapeptide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [GHRL results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Hydrochloric Acid results in increased expression of FOS protein]; Melatonin inhibits the reaction [Capsaicin results in increased expression of FOS protein]
Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]; Capsaicin inhibits the reaction [EGF results in increased localization of FOS protein]
Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS mRNA]; Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GHRL protein inhibits the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]; HTR1B protein inhibits the reaction [Capsaicin results in increased expression of FOS protein]; HTR1D protein inhibits the reaction [Capsaicin results in increased expression of FOS protein]; HTR1F protein inhibits the reaction [Capsaicin results in increased expression of FOS protein]; LY 344864 inhibits the reaction [Capsaicin results in increased expression of FOS protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FOS protein]

PMID:1922926 PMID:9372230 PMID:9580328 PMID:10401552 PMID:10749792 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions
increases expression

N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Capsaicin results in increased expression of FOSL1 protein]

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box A1

decreases expression

Capsaicin results in decreased expression of FOXA1 mRNA

NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188

G

forkhead box E3

increases expression

Capsaicin results in increased expression of FOXE3 mRNA

NCBI chr 5:128,444,912...128,446,494
Ensembl chr 5:128,445,594...128,446,454

G

follistatin-like 1

multiple interactions
increases expression

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FSTL1 protein]; Naproxen inhibits the reaction [Capsaicin results in increased expression of FSTL1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FSTL1 protein]

NCBI chr11:62,895,391...62,948,581
Ensembl chr11:62,779,783...62,948,677

G

FXYD domain-containing ion transport regulator 6

increases expression

Capsaicin results in increased expression of FXYD6 mRNA

NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958

G

gamma-aminobutyric acid type A receptor subunit rho3

increases expression

Capsaicin results in increased expression of GABRR3 mRNA

NCBI chr11:40,902,812...40,955,263
Ensembl chr11:40,902,812...40,955,263

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Capsaicin results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

galanin and GMAP prepropeptide

multiple interactions
increases expression
decreases response to substance

GAL protein promotes the reaction [Capsaicin results in increased secretion of TAC1 protein alternative form]
Capsaicin results in increased expression of GAL mRNA
GAL protein results in decreased susceptibility to Capsaicin

PMID:8971780 PMID:17999197 PMID:18553211 PMID:19112407

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

galanin receptor 2

increases expression

Capsaicin results in increased expression of GALR2 mRNA

NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression
multiple interactions

Capsaicin results in increased expression of GAPDH protein
Capsaicin inhibits the reaction [Dietary Fats results in increased expression of GAPDH protein]

PMID:18991268 PMID:20359164

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

gastrin

increases secretion
decreases secretion

Capsaicin results in increased secretion of GAST protein
Capsaicin results in decreased secretion of GAST protein

PMID:8093880 PMID:19208342 PMID:19296048

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

GATA binding protein 1

increases expression

Capsaicin results in increased expression of GATA1 mRNA

NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530

G

glucagon

multiple interactions

Capsaicin inhibits the reaction [Deoxyglucose results in increased secretion of GCG protein]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

GTP cyclohydrolase 1

affects response to substance

GCH1 gene SNP affects the susceptibility to Capsaicin

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

growth differentiation factor 15

multiple interactions
increases phosphorylation
increases expression

[CEBPB protein binds to GDF15 promoter] promotes the reaction [Capsaicin results in increased expression of GDF15 mRNA]; ATF3 mutant form inhibits the reaction [Capsaicin results in increased expression of GDF15 mRNA]; CEBPB mutant form inhibits the reaction [Capsaicin results in increased expression of GDF15 mRNA]; CEBPB protein promotes the reaction [Capsaicin results in increased expression of GDF15 mRNA]; GSK3B mutant form inhibits the reaction [Capsaicin results in increased expression of GDF15 mRNA]
Capsaicin results in increased phosphorylation of GDF15 protein

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glial fibrillary acidic protein

increases expression
multiple interactions

Capsaicin results in increased expression of GFAP mRNA
Capsaicin results in increased expression of GFAP protein
7-nitroindazole inhibits the reaction [Capsaicin results in increased expression of GFAP protein]; [7-nitroindazole co-treated with pimagedine] promotes the reaction [Capsaicin results in increased expression of GFAP protein]; Capsaicin inhibits the reaction [IL6 protein results in increased expression of GFAP mRNA]; capsazepine inhibits the reaction [Capsaicin results in increased expression of GFAP protein]; pimagedine inhibits the reaction [Capsaicin results in increased expression of GFAP protein]

PMID:18405923 PMID:19285962 PMID:20826152

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

GDNF family receptor alpha 1

affects expression
multiple interactions

Capsaicin affects the expression of GFRA1 protein
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of GFRA1 protein]; Naproxen inhibits the reaction [Capsaicin affects the expression of GFRA1 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of GFRA1 protein]

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473